These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10331827)

  • 21. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes.
    Panyasing Y; Kijtawornrat A; Del Rio C; Carnes C; Hamlin RL
    J Pharmacol Toxicol Methods; 2010; 62(2):148-56. PubMed ID: 20435152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limited induction of torsade de pointes by terikalant and erythromycin in an in vivo model.
    Farkas A; Coker SJ
    Eur J Pharmacol; 2002 Aug; 449(1-2):143-53. PubMed ID: 12163118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
    Othong R; Devlin JJ; Kazzi ZN
    Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
    van Opstal JM; Schoenmakers M; Verduyn SC; de Groot SH; Leunissen JD; van Der Hulst FF; Molenschot MM; Wellens HJ; Vos MA
    Circulation; 2001 Nov; 104(22):2722-7. PubMed ID: 11723026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QT-related proarrhythmic action of sotalol.
    Chézalviel-Guilbert F; Deplanne V; Davy JM; Poirier JM; Xia YZ; Cheymol G; Weissenburger J
    J Cardiovasc Electrophysiol; 1998 May; 9(5):498-507. PubMed ID: 9607458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
    Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperglycemia and subsequent torsades de pointes with marked QT prolongation during refeeding.
    Nakashima T; Kubota T; Takasugi N; Kitagawa Y; Yoshida T; Ushikoshi H; Kawasaki M; Nishigaki K; Ogura S; Minatoguchi S
    Nutrition; 2017 Jan; 33():145-148. PubMed ID: 27544004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New data on the antiarrhythmic value of parenteral magnesium treatment: magnesium and ventricular arrhythmias.
    Perticone F; Ceravolo R; De Novara G; Torchia L; Cloro C
    Magnes Res; 1992 Dec; 5(4):265-72. PubMed ID: 1296762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.
    Kurita T; Ohe T; Shimizu W; Suyama K; Aihara N; Takaki H; Kamakura S; Shimomura K
    Pacing Clin Electrophysiol; 1997 Mar; 20(3 Pt 1):695-705. PubMed ID: 9080496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin.
    Eckardt L; Haverkamp W; Mertens H; Johna R; Clague JR; Borggrefe M; Breithardt G
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):425-34. PubMed ID: 9733356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calmodulin inhibitor W-7 unmasks a novel electrocardiographic parameter that predicts initiation of torsade de pointes.
    Gbadebo TD; Trimble RW; Khoo MS; Temple J; Roden DM; Anderson ME
    Circulation; 2002 Feb; 105(6):770-4. PubMed ID: 11839636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes.
    Batey AJ; Coker SJ
    Br J Pharmacol; 2002 Feb; 135(4):1003-12. PubMed ID: 11861329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.